---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-001155"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2024-01-04T23:59:59+00:00"
generated_at: "2026-06-07T04:04:52.964489+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Black Diamond provides 2024 milestones: Phase 2 data for BDTX-1535 in NSCLC expected Q3; cash into Q2 2025

## Summary
- FDA feedback enables Phase 2 first-line cohort for BDTX-1535 in non-classical EGFR mutant NSCLC; Fast Track granted for second-line C797S.
- Phase 2 results for second/third-line EGFR mutant NSCLC expected Q3 2024; Phase 1 and window-of-opportunity GBM data expected Q2 2024.
- Phase 1 results for BDTX-4933 in KRAS mutant NSCLC expected Q4 2024.
- Existing cash, cash equivalents and investments expected to fund operations into Q2 2025.

## SEC filing metadata
- accession: 0001104659-24-001155
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2024-01-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000110465924001155/0001104659-24-001155-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000110465924001155/tm241770d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-001155
- JSON: https://secwatch.observer/filing/0001104659-24-001155.json
- Plain text: https://secwatch.observer/filing/0001104659-24-001155.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.